Navigation Links
AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
Date:5/15/2008

QUEBEC CITY, May 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Financial Officer, Dennis Turpin, CA, will present a company overview at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 at 9:40 am (local time), in the Atlantique Salon - Meridional (2nd floor) of the Meridien Beach Plaza Hotel at the Sea Club, in Monaco.

A live webcast of this presentation will be available on AEterna Zentaris' website at http://www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

Also on Tuesday, May 20, 2008, Professor, Jurgen Engel, Ph.D., Executive Vice President and Chief Scientific Officer at AEterna Zentaris will make a poster presentation at the American Urological Association's Annual Meeting, from 10:30 am to 12:30 pm (Eastern Time) in Room 315 AB of the Orange County Convention Center in Orlando, Florida. Titled, "Luteinizing Hormone-Releasing Hormone (LHRH) Receptors in BPH as Potential Molecular Targets for Therapy with Cetrorelix", the presentation will focus on the Company's lead compound, cetrorelix, which could provide rapid and long lasting improvement of symptoms in men with benign prostatic hyperplasia.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
2. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
4. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
5. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Announces Changes to its Management Team
8. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
9. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):